Amazfit PPG Outperforms Garmin ECG for AFib Detection, Meta-Analysis Finds

A new meta-analysis is challenging the assumption that Garmin's FDA-approved ECG feature is the gold standard for atrial fibrillation detection on a consumer wrist device. The finding flips the script: continuous PPG monitoring, as used by Amazfit, may catch more real-world AFib cases than a manual ECG snapshot.

The core issue is capture rate. Garmin's ECG requires you to sit still, place your finger on the bezel, and run a 30-second reading. That only works if you happen to trigger it during an AFib episode. Amazfit's continuous PPG system runs passively in the background, which means it has far more chances to flag an irregularity across a full 24-hour window.

The meta-analysis suggests that continuous PPG wins on sensitivity for intermittent AFib precisely because of that exposure time. Garmin's ECG, when used, delivers clinically accurate results comparable to a single-lead medical device. But intermittent AFib, by definition, comes and goes. A snapshot you take after your morning run may simply miss it entirely.

For endurance athletes, this matters more than most. AFib prevalence is significantly higher in long-term endurance athletes than in the general population, with some studies citing rates above 5% in masters runners and cyclists. If your goal is early detection, passive monitoring beats a tool you have to remember to use. Whoop and Polar H10 don't offer ECG at all, and Apple Watch's ECG faces the same on-demand limitation as Garmin's.

The verdict: Garmin's ECG is accurate. It is just not always there when AFib is. Amazfit's continuous PPG approach wins on availability, and in cardiac screening, availability is half the battle.